natgillin/translations-raw huggingface dataset:
Triglycerides in the Cholestagel group increased by 19% and 13% at 6 and 12 weeks vs an increase of 6% and 13% in the placebo group, but the increases were not significantly different.
Vrijednosti triglicerida su u skupini koja je dobivala Cholestagel porasle za 19% u 6. tjednu te za 13% u 12. tjednu, u usporedbi s povišenjem od 6% odnosno 13% u placebo skupini, ali se ta povišenja nisu značajno razlikovala.
However, formal interaction studies with ursodeoxycholic acid have not been performed.
Međutim, nisu provedena formalna ispitivanja interakcija s ursodeoksikolnom kiselinom.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached..
• prilikom svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik,
No clinical data are available on the use of Cholestagel in pregnant women.
Nema kliničkih podataka o primjeni lijeka Cholestagel u trudnica.
180 tablets (1 X 180)
180 tableta (1 x 180)
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP.
Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjenje u dogovorenom Planu upravljanja rizikom (RMP), koji se nalazi u Modulu 1.8.2
If you forget to take Cholestagel
Ako ste zaboravili uzeti Cholestagel
During normal digestion, bile acids are secreted into the intestine.
Tijekom normalne probave žučne se kiseline izlučuju u crijevo.
HDL-C and hsCRP levels were also not significantly different compared to placebo at 12 weeks.
Vrijednosti HDL kolesterola i (visoko osjetljivog) hsCRP-a također se u 12. tjednu nisu značajno razlikovale od onih u placebo skupini.
Cholestagel has no or negligible influence on the ability to drive and use machines.
Cholestagel ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
There were no significant effects on growth, sexual maturation, fat-soluble vitamin levels or clotting factors, and the adverse reaction profile for Cholestagel was comparable to that seen with placebo.
Nisu zabilježeni značajni učinci na rast, spolno sazrijevanje, razinu vitamina topivih u masti ni faktore zgrušavanja, a profil nuspojava kod primjene lijeka Cholestagel bio je usporediv s onim zabilježenim pri primjeni placeba.
There have been very rare reports of reduced phenytoin levels in patients who have received Cholestagel administered with phenytoin.
Vrlo su rijetko prijavljene smanjene razine fenitoina u bolesnika koji su dobivali Cholestagel zajedno s fenitoinom.
Prior to initiating therapy with Cholestagel, if secondary causes of hypercholesterolaemia (i.e., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease) are considered, these should be diagnosed and properly treated.
Ako se prije početka terapije lijekom Cholestagel razmatraju sekundarni uzroci hiperkolesterolemije (npr. loše kontrolirana šećerna bolest, hipotireoza, nefrotski sindrom, disproteinemije, opstruktivna bolest jetre), potrebno ih je dijagnosticirati i pravilno liječiti.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development,
Istraživanja na životinjama ne ukazuju na izravan ili neizravan štetan učinak na trudnoću, razvoj embrija/fetusa, okot i postnatalni razvoj (vidjeti dio 5.3).
For concomitant medications which require administration via divided doses, it should be noted that the required dose of Cholestagel can be taken once a day.
Ako se istodobno uzimaju lijekovi koji se moraju primjenjivati u odvojenim dozama, treba napomenuti da se potrebna doza lijeka Cholestagel može uzeti jedanput na dan.
The effects of combination of fenofibrate and Cholestagel on the risks of myopathy or hepatotoxicity are not known.
Učinci kombinacije fenofibrata i lijeka Cholestagel na rizik od miopatije odnosno hepatotoksičnosti nisu poznati.
Taking Cholestagel helps to lower the level of cholesterol in your blood.
Cholestagel pomaže u snižavanju razine kolesterola u krvi.
However, caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies, such as patients with malabsorption.
Međutim, potreban je oprez u liječenju bolesnika s mogućim nedostatkom vitamina K ili vitamina topivih u masti, kao što su npr. bolesnici s malapsorpcijom.
If you are prescribed Cholestagel and a statin together it is important that you tell your doctor if you are pregnant or if you are planning to become pregnant because statins must not be used during pregnancy; the patient information leaflet that comes with that particular statin should be consulted.
Ako Vam je propisan Cholestagel u kombinaciji sa statinom, važno je da obavijestite liječnika da ste trudni ili da planirate trudnoću jer se statini ne smiju koristiti tijekom trudnoće; svakako pročitajte
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 • Bowel or biliary obstruction
• Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1. • Opstrukcija crijeva ili žučnih vodova.
Cholestagel in combination with statins and in combination with ezetimibe was well tolerated and the adverse reactions observed were consistent with the known safety profile of statins or ezetimibe alone.
Cholestagel se u kombinaciji sa statinima i u kombinaciji s ezetimibom dobro podnosio, a opažene nuspojave bile su u skladu s poznatim profilom sigurnosti statina odnosno ezetimiba primijenjenih samostalno.
Cholestagel is prescribed to treat a condition known as primary hypercholesterolaemia (when cholesterol in the blood is elevated) in adults.
Cholestagel se propisuje za liječenje bolesti koja se zove primarna hiperkolesterolemija (povišene vrijednosti kolesterola u krvi) u odraslih.
SPECIAL STORAGE CONDITIONS Keep the bottle tightly closed in order to protect from moisture.
POSEBNE MJERE ČUVANJA Bočicu čuvati čvrsto zatvorenu radi zaštite od vlage.
Co-administration of Cholestagel and glyburide (also known as glibenclamide) caused a decrease in the AUC0-inf and Cmax of glyburide by 32% and 47%, respectively.
Istodobna primjena lijeka Cholestagel i gliburida (poznatog i kao glibenklamid) izazvala je smanjenje AUC0-inf gliburida za 32% i Cmax za 47%.
Oral contraceptive pill
Oralne kontracepcijske tablete
Your doctor may tell you to take the Cholestagel dose either once a day or twice a day; in either case Cholestagel should be taken with a meal.
Liječnik Vam može reći da dozu lijeka Cholestagel uzimate jedanput na dan ili dvaput na dan, a u svakom slučaju lijek treba uzimati uz obrok.
So far, no studies have been conducted that directly demonstrate whether treatment with Cholestagel as monotherapy or combination therapy has any effect on cardiovascular morbidity or mortality.
Do sada nisu provedena ispitivanja koja bi izravno pokazala utječe li liječenje lijekom Cholestagel u monoterapiji ili u kombiniranoj terapiji na pobol i smrtnost od bolesti srca i krvožilja.
In interaction studies in healthy volunteers, Cholestagel had no effect on the bioavailability of digoxin, metoprolol, quinidine, valproic acid, and warfarin.
U ispitivanjima interakcija u zdravih dobrovoljaca Cholestagel nije utjecao na biorasploživost digoksina, metoprolola, kinidina, valproatne kiseline i varfarina.
Tablets should be taken with liquid and with a meal.
Tablete se moraju uzimati s tekućinom, uz obrok.
In a 6 week study 129 patients with mixed hyperlipidaemia were randomised to fenofibrate 160 mg plus 3.8 g Cholestagel or fenofibrate alone.
U jednom 6-tjednom ispitivanju je 129 bolesnika s miješanom hiperlipidemijom bilo randomizirano u skupinu koja je dobivala fenofibrat od 160 mg i Cholestagel od 3,8 g ili samo fenofibrat.
- Cholestagel may also be used together with ezetimibe (a cholesterol-lowering medicine that works by reducing cholesterol absorption from the gut), with or without a statin.
- Cholestagel se također može koristiti zajedno s ezetimibom (lijek za snižavanje kolesterola koji djeluje tako da smanjuje apsorpciju kolesterola iz crijeva), sa ili bez statina.
Consequently, caution should be exercised when Cholestagel is used in patients with these disorders.
Stoga Cholestagel treba primjenjivati uz oprez u bolesnika s ovim poremećajima.
Printing ink:
Tinta za označavanje:
Apo B decreased by 12%.
Vrijednosti apolipoproteina B (Apo B) bile su snižene za 12%.
In comparison, in patients given placebo, LDL-C, Total-C, HDL-C and Apo-B were unchanged, while triglycerides increased 5%.
Za usporedbu, u bolesnika koji su dobivali placebo, vrijednosti LDL kolesterola, ukupnog kolesterola, HDL kolesterola i Apo B ostale su nepromijenjene, dok su vrijednosti triglicerida porasle za 5%.
During therapy, the cholesterol-lowering diet should be continued, and serum total-C, LDL-C and triglyceride levels should be determined periodically during treatment to confirm favourable initial and adequate long-term responses.
Tijekom terapije treba nastaviti s dijetom za snižavanje kolesterola te periodički određivati razine ukupnog kolesterola, LDL kolesterola i triglicerida u serumu kako bi se potvrdio povoljan početni i odgovarajući dugoročni odgovor na liječenje.
In a clinical study Cholestagel did not affect the faecal excretion of endogenous (hydrophilic) ursodeoxycholic acid.
U kliničkom ispitivanju Cholestagel nije utjecao na izlučivanje endogene (hidrofilne) ursodeoksikolne kiseline fecesom.
The location of such potential obstruction, the degree of obstruction and the presence or absence of normal gut motility would determine treatment.
Terapija se određuje ovisno o mjestu moguće opstrukcije, stupnju opstrukcije te prisutnosti ili odsutnosti normalnog motiliteta crijeva.
No interaction was observed when Cholestagel and pioglitazone were administered simultaneously in healthy volunteers
Nisu opažene interakcije kod istodobne primjene lijeka Cholestagel i pioglitazona u zdravih dobrovoljaca.
Your doctor should only give you Cholestagel if a diet low in fat and cholesterol did not work well enough on its own.
Liječnik će Vam propisati Cholestagel jedino u slučaju kada samo dijetom s niskim udjelom masti i kolesterola nije postignut dovoljan učinak.
If your doctor suspects that Cholestagel may have an effect on the absorption of the other medication, you may be advised to take Cholestagel at least 4 hours before or at least 4 hours after taking the other medication.
Ako liječnik posumnja da bi Cholestagel mogao utjecati na apsorpciju drugih lijekova, možda će Vam preporučiti da Cholestagel uzimate najmanje 4 sata prije ili najmanje 4 sata nakon uzimanja drugog lijeka.
There are no data on the effect of Cholestagel on fertility in humans.
Plodnost Nema podataka o djelovanju lijeka Cholestagel na plodnost u ljudi.
Very rare (may affect up to 1 in 10,000 people): inflammation of the pancreas.
Vrlo rijetko (mogu se javiti u manje od 1 na 10 000 osoba): upala gušterače.
In a 6-month dose-response study in patients with primary hypercholesterolaemia receiving 3.8 or 4.5 g Cholestagel daily, a 15 to 18% decrease in LDL-C levels was observed, which was evident within 2 weeks of administration.
U jednom 6-mjesečnom ispitivanju odgovora na dozu u bolesnika s primarnom hiperkolesterolemijom koji su dobivali 3,8 g ili 4,5 g lijeka Cholestagel na dan, zabilježeno je sniženje razine LDL kolesterola za 15 do 18%, koje je bilo primjetno unutar 2 tjedna primjene.
The mechanism of action for the activity of colesevelam, the active substance in Cholestagel, has been evaluated in several in vitro and in vivo studies.
Mehanizam djelovanja kolesevelama, djelatne tvari u lijeku Cholestagel, ispitan je u nekoliko ispitivanja in vitro i in vivo.
A major portion of bile acids is then absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation.
Najveći dio žučnih kiselina tad se apsorbira iz crijeva i enterohepatičkom cirkulacijom vraća u jetru.
Manufacturer Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Naziv i adresa proizvođača odgovornog(ih) za puštanje serije lijeka u promet Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska
Hypromellose (E464) Diacetylated monoglycerides
hipromeloza (E464) diacetilirani monogliceridi
For patients on ciclosporin starting or stopping Cholestagel or patients on Cholestagel with a need to start ciclosporin: Cholestagel reduces the bioavailability of ciclosporin (see also section 4.5).
Za bolesnike na terapiji ciklosporinom koji započinju ili prekidaju terapiju lijekom Cholestagel ili bolesnike na terapiji lijekom Cholestagel koji moraju početi uzimati ciklosporin: Cholestagel smanjuje bioraspoloživost ciklosporina (vidjeti dio 4.5).
When Cholestagel was co-administered with statins in clinical studies, an expected add-on LDL-C lowering effect was observed, and no unexpected effects were observed.
Kada je u kliničkim ispitivanjima Cholestagel primjenjivan zajedno sa statinima, opažen je očekivan dodatni učinak na sniženje LDL kolesterola, a nisu primijećeni nikakvi neočekivani učinci.
180 tablets without carton
180 tableta bez kutije
Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density lipoprotein cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.
Cholestagel je u kombinaciji s inhibitorom 3-hidroksi-3-metil-glutaril-koenzim A (HMG-CoA) reduktaze (statinom) indiciran kao adjuvantna terapija uz dijetu, kako bi se dodatno smanjile razine lipoproteina male gustoće (LDL kolesterola) u odraslih bolesnika s primarnom hiperkolesterolemijom koja se ne može dovoljno dobro kontrolirati samo statinom.
In the paediatric population, the safety and efficacy of 1.9 or 3.8 g/day Cholestagel was assessed in an 8 week multi-centre, randomised, double-blind, placebo-controlled study in 194 boys and postmenarchal girls, aged 10-17 years, with heterozygous FH on a stable dose of statins (47 patients, 24%) or treatment-naïve to lipid-lowering therapy (147 patients, 76%).
U pedijatrijskoj je populaciji sigurnost i djelotvornost lijeka Cholestagel u dozama od 1,9 g ili 3,8 g na dan ocijenjena u multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju sa 194 dječaka i djevojčica nakon menarhe, u dobi od 10 do 17 godina, s heterozigotnom obiteljskom hiperkolesterolemijom, koji su uzimali stabilnu dozu statina (47 bolesnika, 24%) ili još nisu bili liječeni lijekovima za snižavanje lipida (147 bolesnika, 76%).
This interaction was also observed when Cholestagel was administered one hour after the oral contraceptive pill.
Ta je interakcija zabilježena i kada je Cholestagel primijenjen jedan sat nakon uzimanja oralne kontracepcijske tablete.
• Ursodeoxycholic acid (a medicine used to dissolve gallstones or treat specific chronic liver diseases).
• ursodeoksikolne kiseline (lijeka koji se koristi za rastapanje žučnih kamenaca ili za liječenje određenih kroničnih bolesti jetre).
Uncommon (may affect up to 1 in 100 people): muscle pain, raised levels of liver enzymes in your blood, difficulty in swallowing.
Manje često (mogu se javiti u manje od 1 na 100 osoba): bolovi u mišićima, povišene vrijednosti jetrenih enzima u krvi, otežano gutanje.
Only constipation and dyspepsia were reported by a higher percentage among those receiving Cholestagel, compared with placebo.
Samo su konstipacija i dispepsija prijavljene u većem postotku u bolesnika koji su dobivali Cholestagel u usporedbi s onima koji su dobivali placebo.
High density polyethylene bottles with a polypropylene cap without outer carton.
Bočice od polietilena visoke gustoće s polipropilenskim zatvaračem bez vanjske kutije.
These compensatory effects result in increased clearance of LDL-C from the blood, resulting in decreased serum LDL-C levels.
Rezultat ovih kompenzacijskih učinaka je povećan klirens LDL kolesterola iz krvi, što dovodi do smanjenja razina LDL kolesterola u serumu.
Multi-centre, randomised, double-blind, placebo-controlled studies in 487 patients demonstrated an additive reduction of 8 to 16% in LDL-C when 2.3 to 3.8 g Cholestagel and a statin (atorvastatin, lovastatin or simvastatin) were administered at the same time.
Multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja s 487 bolesnika pokazala su dodatno sniženje LDL kolesterola za 8 do 16% kod istodobne primjene lijeka Cholestagel u dozi od 2,3 g do 3,8 g i jednog od statina (atorvastatin, lovastatin ili simvastatin).
• Anti-epileptic medicines (medicines, such as phenytoin, used to treat epilepsy).
• antiepileptika (lijekova za liječenje epilepsije, npr. fenitoina).
Your liver uses cholesterol from your blood to do this, which lowers the level of cholesterol in your blood.
Za to jetra koristi kolesterol iz krvi, što snižava njegovu razinu u krvi.
Colesevelam is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption.
Kolesevelam je polimer koji snižava razine lipida, ne apsorbira se i veže žučne kiseline u crijevima i tako sprječava njihovu ponovnu apsorpciju.
Colesevelam binds to glimepiride and reduces glimepiride absorption from the gastrointestinal tract.
Kolesevelam se veže za glimepirid i smanjuje apsorpciju glimepirida iz probavnog trakta.
The combination of ezetimibe 10 mg and Cholestagel 3.8 g daily therapy in the absence of a statin resulted in a significant combined effect for LDL-C lowering by 32% demonstrating an additional effect of 11% LDL-C lowering with Cholestagel and ezetimibe compared to ezetimibe alone.
Kombinacija ezetimiba u dozi od 10 mg i lijeka Cholestagel u dozi od 3,8 g na dan, bez statina, rezultirala je značajnim kombiniranim učinkom na sniženje LDL kolesterola za 32%, što znači da je kombinacija lijeka Cholestagel i ezetimiba dodatno snizila vrijednosti LDL kolesterola za 11% u usporedbi s ezetimibom samim.
Package sizes are: 180 tablets (1 X 180)
Veličine pakiranja su: 180 tableta (1 x 180)
Iron oxide black (E172) Hypromellose (E464) Propylene glycol
crni željezov oksid (E172) hipromeloza (E464) propilenglikol
Elderly population
Stariji bolesnici
However no interaction was observed when Cholestagel was administered four hours after the oral contraceptive pill.
Međutim, interakcija nije zabilježena kada je Cholestagel primijenjen 4 sata nakon uzimanja oralne kontracepcijske tablete.
If you are taking anticoagulant therapy you should consult with your physician to closely monitor anticoagulation levels, as Cholestagel may affect the absorption of vitamin K and therefore interfere with the activity of warfarin.
Ako uzimate antikoagulantne lijekove, morate se posavjetovati s liječnikom kako bi pažljivo kontrolirao razinu antikoagulacije budući da Cholestagel može utjecati na apsorpciju vitamina
No interaction was observed when glimepiride was taken at least 4 hours before colesevelam.
Nije opažena interakcija pri uzimanju glimepirida najmanje 4 sata prije kolesevelama.
In these patients, monitoring vitamin A, D and E levels and assessing vitamin K status through the measurement of coagulation parameters is recommended and the vitamins should be supplemented if necessary.
U tih se bolesnika preporučuje praćenje vrijednosti vitamina A, D i E i procjena statusa vitamina
- Cholestagel may be used together with a statin and the diet low in fat and cholesterol when patients are not appropriately controlled by the statin on its own.
- Cholestagel se može koristiti zajedno sa statinom i uz dijetu s niskim udjelom masti i kolesterola kada se stanje bolesnika ne može dovoljno dobro kontrolirati samo statinom.
Very common (may affect more than 1 in 10 people): flatulence (wind), constipation.
Vrlo često (mogu se javiti u više od 1 na 10 osoba): vjetrovi, zatvor.
Very common: Flatulence*, constipation* Common: Vomiting, diarrhoea*, dyspepsia*, abdominal pain, abnormal stools, nausea, abdominal distension
Često: povraćanje, proljev*, dispepsija*, bol u abdomenu, poremećaj stolice, mučnina, distenzija abdomena Manje često: disfagija
If you stop taking Cholestagel Your cholesterol may increase to the level it was before treatment was started.
Vrijednosti kolesterola mogu se povisiti na razinu prije početka liječenja.
Before starting therapy with Cholestagel, you should be advised to follow a cholesterol-lowering diet and you should continue this diet during treatment.
Prije početka liječenja lijekom Cholestagel liječnik Vam mora preporučiti dijetu za snižavanje kolesterola koju morate nastaviti tijekom trajanja terapije.
Not known: Intestinal obstruction*,** Musculoskeletal and connective tissue disorders Uncommon: Myalgia
Nepoznato: intestinalna opstrukcija*,**
For statin-naïve patients on monotherapy, Cholestagel resulted in a statistically significant LDL-C reduction of 12% at 3.8 g/day and 7% at 1.9 g/day, versus a 1% reduction in the placebo group (see section 4.2).
U bolesnika koji prethodno nisu uzimali statine, monoterapijom lijekom Cholestagel postignuto je statistički značajno sniženje LDL kolesterola od 12% uz dozu od 3,8 g na dan, odnosnoi 7% uz dozu od 1,9 g na dan, u usporedbi sa sniženjem od 1% u placebo skupini (vidjeti dio 4.2).
Each tablet contains 625 mg colesevelam.
Jedna tableta sadrži 625 mg kolesevelama.
Cholestagel did not induce any clinically significant reduction in the absorption of vitamins A, D, E or K during clinical studies of up to one year.
Tijekom kliničkih ispitivanja u trajanju do godine dana Cholestagel nije izazvao klinički značajno smanjenje apsorpcije vitamina A, D, E ili K.
A MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE
The most frequently occurring adverse reactions are flatulence and constipation, found within the gastrointestinal disorders system organ class.
Sažetak sigurnosnog profila Najčešće nuspojave su flatulencija i konstipacija, koje prema klasifikaciji organskih sustava pripadaju poremećajima probavnog sustava.
6.6 Instructions precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
How to take Cholestagel
Kako uzimati Cholestagel
The effect of 3.8 g Cholestagel plus 10 mg ezetimibe versus 10 mg ezetimibe alone on LDL-C levels was assessed in a multicentre, randomised, double-blind, placebo-controlled, parallel-group study in 86 patients with primary hypercholesterolaemia over a 6-week treatment period.
Učinak lijeka Cholestagel od 3,8 g zajedno s 10 mg ezetimiba na vrijednosti LDL kolesterola, u usporedbi s primjenom samo ezetimiba u dozi od 10 mg, ispitan je u multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju s paralelnim skupinama, u 86 bolesnika s primarnom hiperkolesterolemijom tijekom šestotjednog liječenja.
• Anticoagulant therapy (medicines, such as warfarin, used to thin blood).
• antikoagulantnih lijekova (lijekova za razrjeđivanje krvi, npr. varfarina).
Cholestagel works in your intestinal system by binding bile acids produced by your liver and carrying the bile acids out of your body with your faeces.
Cholestagel djeluje u probavnom sustavu tako što veže žučne kiseline koje stvara jetra i stolicom ih izlučuje iz tijela.
Before starting therapy with Cholestagel, your physician should make sure that certain conditions do not contribute to your elevated cholesterol levels.
Prije početka liječenja lijekom Cholestagel Vaš se liječnik mora uvjeriti da Vašim povišenim razinama kolesterola ne pridonose određena stanja ili bolesti.
It is important that you take olmesartan at least 4 hours before you take Cholestagel.
Važno je da olmesartan uzmete najmanje 4 sata prije uzimanja lijeka Cholestagel.